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Abstract
We investigated the frequency of remission according to the
disease activity score (DAS28) definition, modified American
Rheumatology Association (ARA) criteria, and the frequency of
an achievement of a functional status above defined thresholds
('functional remission', 'physical independence') in rheumatoid
arthritis (RA) patients treated with either biologics or
conventional DMARDs. We used the data of a prospective
cohort study, the German biologics register RABBIT (German
acronym for Rheumatoid Arthritis – Observation of Biologic
Therapy) to investigate the outcomes in RA patients with two or
more DMARD failures who received new treatment with
biologics (BIOL; n = 818) or a conventional DMARD (n = 265).
Logistic regression analysis was applied to adjust for
differences in baseline risks. Taking risk indicators such as
previous DMARD failures or baseline clinical status into
account, we found that biologics doubled the chance of
remission compared to conventional DMARD therapies (DAS28
remission, adjusted odds ratio (OR) 1.95 (95% confidenece
interval (CI) 1.2–3.2)); ARA remission, OR 2.05 (95% CI 1.2–
3.5)). High remission rates (DAS28 remission, 30.6%; ARA
remission, 16.9%) were observed in BIOL patients with a
moderate disease activity (DAS28, 3.2 to 5.1) at the start of
treatment. These rates decreased to 8.5% in patients with
DAS28 > 6. Sustained remission at 6 and 12 months was
achieved in <10% of the patients. Severely disabled patients
(≤50% of full function) receiving biologic therapies were
significantly more likely to achieve a status indicating physical
independence (≥67% of full function) than controls (OR 3.88
(95% CI 1.7–8.8)). 'Functional remission' (≥83% of full function)
was more often achieved in BIOL than in controls (OR 2.18
(95% CI 1.04–4.6)). In conclusion, our study shows that
biologics increase the chance to achieve clinical remission and
a status of functional remission or at least physical
independence. However, temporary or even sustained
remission remain ambitious aims, which are achieved in a
minority of patients only.
Introduction
Considering all available therapeutic options, today's treat-
ment of rheumatoid arthritis (RA) differs substantially from
what it was a decade ago. The main objectives in the treatment
of RA are now to induce remission, to prevent joint destruction
and to enable the patient to lead a full life. The efficacy of inf-
ARA = American Rheumatology Association; BIOL = patients treated with biologics; CI = confidence interval; CON = patients receiving conventional 
DMARD treatment (control group); CRP = C-reactive protein; DAS28 = disease activity score based on 28 joint counts; DMARD = disease modifying 
anti-rheumatic drugs; HAQ = Health Assessment Questionnaire; ESR = erythrocyte sedimentation rate; FFbH = Funktionsfragebogen Hannover 
(Hannover Functional Status Questionnaire); MTX = methotrexate; OR = odds ratio; RA = rheumatoid arthritis; RABBIT = German biologics register 
(German acronym for Rheumatoid Arthritis – Observation of Biologic Therapy); SJC = 28-joint count of swollen joints; TJC = 28-joint count of tender 
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liximab, etanercept, adalimumab, and anakinra was demon-
strated in randomized controlled trials in the majority of RA
patients enrolled [1-5]; however, less is known regarding the
effectiveness of these drugs in daily rheumatological care.
Standard patients differ from those enrolled into randomized
controlled trials [6] with regard to disease severity, treatment
history, and comorbidity. Randomized clinical trials usually
focus on demonstrating relative rather than absolute improve-
ment. In the treatment of individual patients, however, it is cru-
cial to reach absolute targets like remission, low inflammatory
activity, no pain, or a high functional capacity [7].
From the perspective of the patient, absence of pain and func-
tional ability are the major goals. Functional independence, if
not even normal function, are, therefore, major benefits that
patients expect from novel therapies.
Taking physician-related and patient-related outcomes into
account, two types of treatment outcomes are investigated:
the percentage of patients who achieve remission according
to either the disease activity score [8], or to modified American
Rheumatology Association (ARA) criteria [9]; and the percent-
age of patients who reach either functional independence in
daily activities after having been severely disabled (help
dependent) at baseline or achieve (nearly) normal function
('functional remission') after a previous functional status of
below physical independence at baseline. We used the data
of a prospective cohort study, the German biologics register
RABBIT (German acronym for Rheumatoid Arthritis – Obser-
vation of Biologic Therapy) for patients on biologic treatments
as well as those on conventional disease modifying anti-rheu-
matic drug (DMARD) therapy.
Materials and methods
Patients
Patients aged 18 to 75 years meeting the American College
of Rheumatology criteria for RA who were enrolled into RAB-
BIT between 1 May 2001 and 31 December 2003 were eligi-
Table 1
Baseline characteristics.
Characteristic Etanercept Infliximab Adalimumab Anakinra Biologics total Control
N 397 255 121 45 818 265
Age 53.2 (12.5) 54.0 (12.3) 53.8 (12.4) 56.2 (11.2) 53.7 (12.3) 57.4 (10.3)
Female (%) 79.1 71.0 85.1 73.3 76.6 83.8
Disease duration (years), median (IQR) 10 (6–18) 9 (5–14) 12 (7–19) 13 (7–21) 10 (6–17) 9 (5–17)
Rheumatoid factor positive (%) 82.1 83.5 84.3 77.8 82.2 77.7
Swollen joint count 10.2 (6.2) 11.3 (6.4) 9.6. (6.4) 10.9 (6.6) 10.5 (6.3) 8.2 (5.3)
Tender joint count 13.0 (7.3) 13.0 (7.4) 12.3 (7.4) 13.6 (7.3) 12.9 (7.3) 10.5 (6.9)
ESR (mm/h), median (IQR) 33 (20–54) 32 (18–54) 30 (17–44) 36 (22–51) 32 (18–53) 23 (14–37)
CRP (mg/l), median (IQR) 20 (7–42) 18 (7–48) 18 (7–32) 21 (6–36) 18 (7–42) 12 (4–27)
DAS28 6.1 (1.1) 6.2 (1.2) 5.9 (1.2) 6.3 (1.0) 6.1 (1.1) 5.5 (1.1)
FFbH 53.4 (22.9) 52.8 (20.9) 53.2 (25.1) 52.7 (23.3) 53.1 (22.8) 61.4 (22.4)
Number of previous DMARDs 3.9 (1.3) 3.9 (1.4) 4.4 (1.3) 4.3 (1.6) 4.0 (1.4) 2.8 (0.9)
Current treatment DMARD (%)
MTX alone 33.0 67.5 43.0 60.0 46.7 1.5
Other single DMARD 11.9 14.5 8.3 8.8 12.0 29.8
Combination of two DMARDs 5.3 8.6 5.8 4.4 6.4 57.3
Combinations of three DMARDs 1.3 1.6 1.6 0.0 1.3 11.3
No DMARD 48.6 7.8 41.3 26.7 33.6 0
Biologic dose/week (mg)a 49.7 (4.1) 4.0 (1.9) 21.5 (7.0) 700 (0) - -
Comorbidity (%) 72.6 68.5 64.5 71.1 70.0 72.8
Osteoporosis (%) 30.2 27.9 22.3 35.6 28.6 18.5
Values are means and standard deviations if not otherwise specified. CRP, C-reactive protein; DAS28, disease activity score based on 28 joint 
counts; DMARD, disease modifying anti-rheumatic drugs; ESR, erythrocyte sedimentation rate; FFbH, Funktionsfragebogen Hannover (Hannover 
Functional Status Questionnaire); IQR, inter quartile range. aEtanercept, adalimumab and anakinra, mean dosage/week; infliximab, mean dosage/
8 weeks and kg body weight, time intervals between the applications were taken into account.Available online http://arthritis-research.com/content/8/3/R66
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ble for the following analysis. RABBIT is an ongoing long-term
prospective cohort study of RA patients treated with biologics
or conventional DMARDs in daily rheumatological care.
Patients are eligible as 'cases' if a new treatment with inflixi-
mab, etanercept, anakinra (since January 2003) or adalimu-
mab (since September 2003) is started and as 'controls' if a
conventional DMARD therapy is started after the failure of at
least one other DMARD. Patients were required to give written
informed consent at the time of enrolment. (for further details,
see [10,11]). For better comparability of the groups, we
excluded those patients from the following analysis who had
only one DMARD failure, no failure of a methotrexate (MTX)
therapy, who received the new treatment ≥1 day before study
entry or who had a low disease activity at baseline (disease
activity score based on 28 joint count (DAS28 [12]) <3.2).
The visit at 12 months was necessary for the assessment of
the outcome. We excluded patients who missed the 12
months' visit (n = 179) because those patients did not differ
significantly from patients who attended at 12 months (n =
1,083) with respect to important patient characteristics at
baseline (age, number of DMARD failures, DAS28, joint
counts, functional status). This applied to cases as well as to
controls.
Assessments
At baseline and at 3, 6, and 12 months' of follow-up, the treat-
ing rheumatologist recorded a 28 joint count of tender (TJC)
and swollen (SJC) joints, erythrocyte sedimentation rate (ESR;
Westergren method), C-reactive protein (CRP), morning stiff-
ness, DMARD and/or biologic therapy, including details of
start/end, reasons for treatment termination, concomitant ther-
apies with glucocorticoids, non-steroidal anti-inflammatory
drugs (NSAIDs), and adverse events. Patients self-assessed
their pain, general health or fatigue on a numerical rating scale
of 0 to 10. Disability was assessed by means of the Hannover
Functional Status Questionnaire (Funktionsfragebogen Han-
nover, FFbH). The FFbH measures limitations in activities of
daily living and it is comparable to the Health Assessment
Questionnaire (HAQ). Scores are given in percent of full func-
tion (range 0 to 100) and can be transformed into HAQ values
[13-15].
Endpoints
Endpoints were remission according to DAS28 or to modified
ARA criteria [9,16] as well as physical independence and
'functional remission'.
Clinical remission was defined as DAS28 <2.6 (DAS28 remis-
sion) [8] and according to the following modification of the
ARA criteria [16]: 4 out of 5 criteria had to be fulfilled at one
point in time: no tender joints; no swollen joints; ESR <30 mm/
h for females or <20 mm/h for males; morning stiffness <15
minutes; pain ≤1 on a 0 to 10 scale.
'Physical independence' was defined as FFbH ≥67. This cut
off point was used according to the study of Westhoff and col-
leagues [13], which showed that patients with an FFbH of ≥67
can be expected to be physically independent. 'Functional
remission' was defined as FFbH >83. This cut off point was
derived from data from 12,303 RA patients recorded in the
German rheumatologic database [17] in 2003. We selected
patients who were rated as Steinbrocker's functional class I by
the rheumatologist [18] and who in addition rated their func-
tional disability on a 0 to 10 numerical rating scale (0 = best
functional status) as 0 or 1. More than 90% of these 1,041
patients had an FFbH >83.
The objective was to investigate the frequency of endpoints
achieved at 12 months and the frequency of achievements
sustained over a six month period. We excluded patients with
a low disease activity (DAS28 <3.2) before start of treatment
and we performed subgroup analyses with respect to the func-
tional outcome. Changes in the treatment were not taken into
account, as we did not aim to compare drugs directly.
Statistics
Patients who received treatment with biologics had a more
severe and more active disease than those receiving conven-
tional DMARD therapies. Therefore, multivariate logistic
regression was applied to adjust for confounding by indica-
tion. The adjustment was done at two consecutive stages.
At the first stage, a logistic regression estimate of the likeli-
hood (propensity score) of being treated with biologics was
made for each patient using baseline characteristics. This cal-
culation was based on recent findings [10]. To estimate the
propensity score, the final model included age, gender,
number of previous DMARDs, DAS28, ESR, FFbH, and oste-
oporosis as well as previous treatment with cyclosporine A as
Table 2
Patients in remission at 12 months according to DAS28 and to 
modified ARA criteria.
Baseline 
status
Patients in DAS28 
remission, n (%)
Patients in modified ARA 
remission, n (%)
DAS28 BIOL 
(n = 775)
CON 
(n = 255)
BIOL 
(n = 764)
CON 
(n = 256)
>3.2 to 4.0 16 (45.7) 8 (33.3) 9 (26.5) 4 (16.0)
>4.0 to 5.1 33 (26.4) 16 (23.2) 18 (14.3) 10 (14.5)
>5.1 to 6.0 40 (22.1) 10 (13.5) 38 (20.9) 8 (10.8)
>6.0 to 7.0 28 (11.1) 4 (6.3) 25 (10.1) 3 (4.8)
> 7.0 9 (5.0) 1 (4.0) 11 (6.3) 1 (3.8)
Total 126 (16.3) 39 (15.3) 101 (13.2) 26 (10.2)
ARA, American Rheumatology Association; BIOL, patients treated 
with biologics; CON, patients receiving conventional DMARD 
treatment (control group); DAS28, disease activity score based on 
28 joint counts.Arthritis Research & Therapy    Vol 8 No 3    Listing et al.
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additional markers of disease severity. The propensity score
model fit well. There was no significant difference between
observed and predicted frequencies by deciles at risk (Hos-
mer-Lemeshow test, p = 0.25). Furthermore, there was a com-
plete overlap of the propensity scores of patients treated with
biologics (BIOL) and patients receiving conventional DMARD
treatment (control group; CON). It was possible, therefore, to
use the propensity score as an additional risk factor of remis-
sion or functional outcome. This approach allows the adjust-
ment for confounding by indication, which is for removing the
bias in the outcome due to the covariates included in the pro-
pensity score [19].
At the second stage, logistic regression was applied to inves-
tigate which factors predicted remission or the two functional
endpoints (independence and functional remission). The pro-
pensity score was included in the models as one prognostic
factor. The final multivariate logistic regression models were
identified by stepwise regression. These models were used for
the calculation of adjusted odds ratios (ORs).
In a second approach we used the propensity score (scale: 0
to 1) to match cases (BIOL) and controls directly [19]. For
each pair, a maximal difference of 0.05 propensity score units
was allowed.
In the univariate and multivariate analyses, 98% of the patients
had complete baseline data for all parameters considered.
Outcome parameters were complete in 93% to 97% of the
patients. Therefore, no imputation technique for missing data
Table 3
Odds ratios (OR) of remission at 12 months.
Remission according to DAS28 (DAS28 <2.6) Remission according to modified ARA criteria
Univariate Multivariate Univariate Multivariate
OR 95% CI Adj. OR 95% CI OR 95% CI Adj. OR 95% CI
DAS28 0.53 0.45–0.62 0.46 0.35–0.61 0.69 0.59–0.82
Propensity score (scale: 0 to 1)a 0.86 0.80–0.93 0.89 0.80–0.99 0.92 0.85–1.00 0.84 0.75–0.94
Rheumatoid factor positive 0.51 0.35–0.75 0.68 0.44–1.06
ESRb 0.75 0.68–0.82 0.92 0.85–1.00
CRPb 0.94 0.89–1.00 0.96 0.90–1.01
Swollen joint count 0.93 0.91–0.96 0.96 0.93–0.99
Tender joint count 0.94 0.92–0.97 1.05 1.01–1.09 0.94 0.92–0.97
FFbHb 1.26 1.17–1.37 1.21 1.11–1.32 1.13 1.03–1.25
No. of previous DMARD
4 to 5 versus 2 to 3 0.68 0.47–0.97 0.74 0.50–1.10
≥6 versus 2 to 3 0.47 0.24–0.91 0.53 0.26–1.10
Female 0.88 0.59–1.31 1.06 0.67–1.69
Ageb 0.68 0.59–0.78 0.74 0.62–0.87 0.72 0.62–0.84 0.72 0.61–0.85
Disease duration (years) 0.98 0.96–1.00 0.99 0.96–1.00
Disease duration ≤2 years versus >2 
years
1.86 0.97–3.58 0.81 0.32–2.09
Any comorbidity yes versus no 0.52 0.37–0.73 0.68 0.46–1.01
Osteoporosis yes versus no 0.38 0.23–0.61 0.51 0.30–0.87 0.69 0.44–1.10
BIOL versus CON 1.08 0.73–1.59 1.95 1.20–3.19 1.35 0.85–2.13 2.05 1.19–3.52
Anti-TNF agents versus CON 1.10 0.74–1.63 1.97 1.20–3.21 1.39 0.88–2.20 2.09 1.22–3.59
Anakinra versus CON 0.71 0.26–1.91 1.66 0.56–4.91 0.68 0.20–2.36 1.19 0.33–4.34
Results of different univariate and multivariate logistic regression analyses. Final multivariate models were found by stepwise regression. aOdds 
ratios (ORs) refer to 0.1 units of the propensity score. bThe ORs refer to 10 units of the parameter. Adj. OR, adjusted odds ratio; ARA, American 
Rheumatology Association; BIOL, patients treated with biologics; CI, confidence interval; CON, patients receiving conventional DMARD 
treatment (control group); CRP, C-reactive protein; DAS28, disease activity score based on 28 joint counts; DMARD, disease modifying anti-
rheumatic drugs; ESR, erythrocyte sedimentation rate; FFbH, Funktionsfragebogen Hannover (Hannover Functional Status Questionnaire); TNF, 
tumor necrosis factor.Available online http://arthritis-research.com/content/8/3/R66
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was applied. The Kruskal-Wallis test, Mann-Whitney test, and
chi-square test were used to compare the baseline character-
istics of the patients. The McNemar test was applied to com-
pare frequencies between different time points and to
compare the remission rates in the matched pairs analysis.
Results
Baseline characteristics
A total of 1,083 patients fulfilled the inclusion criteria. Among
these, 818 patients had started treatment with biologics
(BIOL) and 265 had started a new DMARD therapy at base-
line (CON) (Table 1). The BIOL patients were younger (p <
0.0001) and had a significantly more active disease (DAS28,
p < 0.0001; SJC, p < 0.0001; CRP, p < 0.0001). Furthermore
they were more limited in activities involved in daily living
(mean FFbH 53.1% of full function in the BIOL group versus
61.4% in the CON group, p < 0.0001; Table 1). At enrolment
the treatment was changed in all patients. The last treatment
before this change included MTX (BIOL, 56.4%; CON,
72.9%), leflunomide (BIOL, 45.0%; CON, 12.4%), sul-
phasalazine (BIOL, 14%; CON, 18%), other DMARDs (<15%
each) or biologics (BIOL, 15.4%; CON, 3.5%). This previous
treatment was applied as a combination of two or more
DMARDs in 28% of the controls and 40% of the BIOL
patients. In total, BIOL patients had a longer treatment history
with DMARDs and significantly more previous DMARD fail-
ures (4.0 ± 1.4 versus 2.8 ± 0.9, p < 0.001; see also [10]).
Remission after one year of treatment
According to the two different criteria, 10% to 16% of the
patients achieved remission (Table 2), and 72% of the patients
who fulfilled the modified ARA criteria for remission also ful-
filled the DAS28 criteria (BIOL, 70.7%). Among those who
were in DAS28 remission, however, only 54.9% also fulfilled
the modified ARA criterion. Baseline DAS28 was strongly pre-
dictive of the achievement of remission (Table 2). High remis-
sion rates (DAS28 remission, 30.6%; ARA remission, 16.9%)
were observed in BIOL patients with a moderate disease activ-
ity (DAS28, 3.2 to 5.1) at the start of treatment. These rates
decreased to 8.5% (95% confidence interval (CI), 6.2% to
11.5%) in patients with DAS28 >6.0 for both types of remis-
sion. Highly significant negative associations between DAS28
at the start of treatment and remission at 12 months were also
found by logistic regression (p < 0.0001) for both types of
remission. These associations were stronger than those
between single activity markers (SJC, TJC, ESR, CRP) and
remission (Table 3). A lower functional capacity and a higher
age were found to reduce significantly the chance of both
types of clinical remission. This was also true if DAS28 at
baseline and treatment group were controlled for (data not
shown). Furthermore, patients with more than three DMARD
failures, or patients with osteoporosis, had a lower chance of
DAS28 remission. Patients with a disease duration ≤2 years
had a higher chance of DAS28 remission, but the association
did not reach statistical significance (p = 0.07), even if DAS28
at baseline and treatment group were controlled for (p = 0.06,
data not shown) as the number of patients with recent onset
RA was low (BIOL, n = 46; CON, n = 17).
The multivariate logistic regression models resulted in a dou-
bled chance of remission (OR = 1.95 for DAS28 remission (p
= 0.006); OR = 2.05 for ARA remission (p = 0.007)) for
patients receiving biologics compared to those treated with
conventional DMARDs (Table 3). The propensity score
remained significant in both models, indicating that patients
who had a high likelihood of being treated with biologics had
a significantly lower a priori chance of remission.
Ninety-four percent of the BIOL patients were treated with
anti-tumor necrosis factor (TNF) agents. Therefore, the
adjusted ORs changed only slightly if the subgroup of patients
receiving anti-TNF agents were compared with controls sepa-
Table 4
Matched pairs analysis: patients' characteristics and rates of 
remission at 12 months.
BIOL CON p valuea
N1 9 3 1 9 3
Characteristics at baseline
Age 54.7 (12.1) 55.9 (10.3) 0.50
Female (%) 83.4 79.8 0.43
Rheumatoid factor positive 
(%)
82.4 79.8 0.60
Swollen joint count 8.7 (6.1) 8.8 (5.5) 0.59
Tender joint count 11.3 (7.3) 11.4 (6.8) 0.61
ESR (mm/h), median (IQR) 22 (13–40) 24 (15–40) 0.37
CRP (mg/L), median (IQR) 14 (6–28) 12 (5–29) 0.19
DAS28 6.1 (1.1) 6.1 (1.1) 0.54
FFbH 59.3 (21.1) 58.9 (22.6) 0.92
No. previous DMARDs 3.1 (1.1) 3.0 (1.0) 0.74
Propensity score 0.63 (0.19) 0.63 (0.19) -
Remission at 12 months, n 
(%)
DAS28 Remission 48 (24.9%) 24 (12.4%) 0.004
Remission according to 
modified ARA criteria
31 (16.1%) 16 (8.3%) 0.036
In this analysis pairs of BIOL and CON patients who differed by less 
than 0.05 on the propensity score scale were included. Values are 
means and standard deviations if not otherwise specified. aMann-
Whitney test and chi-square test were applied as appropriate for the 
comparision of the baseline characteristics and McNemar test for the 
comparison of the remission rates. ARA, American Rheumatology 
Association; BIOL, patients treated with biologics; CON, patients 
receiving conventional DMARD treatment (control group); CRP, C-
reactive protein; DAS28, disease activity score based on 28 joint 
counts; DMARD, disease modifying anti-rheumatic drugs; ESR, 
erythrocyte sedimentation rate; FFbH, Funktionsfragebogen 
Hannover (Hannover Functional Status Questionnaire); IQR, inter 
quartile range.Arthritis Research & Therapy    Vol 8 No 3    Listing et al.
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rately (Table 3). The ORs for the anakinra patients were lower,
but they have to be interpreted with caution as the number of
anakinra patients was small. We also compared the subgroup
of patients receiving anti-TNF agents alone with the subgroup
of patients treated with anti-TNF agents in combination with
MTX. Taking prognostic factors of remission into account, no
significant differences in the remission rates (DAS28 remis-
sion, p = 0.76; ARA remission, p = 0.87) were found.
The results found in the matched pairs analysis were very sim-
ilar to those found by multivariate logistic regression with the
propensity score as one covariate. There were 193 pairs who
fulfilled the matching criteria. The pairs had similar patient
characteristics at the start of treatment (Table 4). There was a
highly significant difference in the remission rates between the
treatment groups (DAS28 remission, OR 2.14 (95% CI 1.29–
3.67); remission according to the modified ARA criteria, OR
2.00 (95% CI 1.08–3.72)).
Sustained remission
In patients who achieved remission, a considerable risk of
relapse some months later was observed. Only 44/102
(43.1%: BIOL, 32/72 (44.4%); CON, 12/30 (40%)) who
were in remission after six months according to the ARA crite-
ria remained in remission at 12 months. The corresponding fig-
ures for DAS28 remission are shown in Table 5. In total,
sustained remission rates of 7.7% for DAS28 and 4.5% for
ARA remission were found in patients receiving biologics.
As shown in Table 5, 24 cases were not in remission but had
a DAS28 <3.2 at 12 months, while 35 patients (26.3%) dete-
riorated to a state of moderate or high disease activity. In 5
(BIOL, n = 3) of these 35 patients, the treatment was stopped
between months 6 and 12 because of adverse events or non-
compliance; therefore, treatment termination did not explain
the increase. By logistic regression the number of previous
DMARD failures was identified as a significant (p = 0.02) risk
factor for change from remission to moderate or high disease
activity. Patients with 4 to 5 (>5) DMARD failures had an OR
for switching of 2.7 (CI 1.2–6.3) compared to patients with
two or three failures; 4.0 (CI 1.1–15.0) for patients with >5
DMARD failures. This risk factor also explained the difference
in the crude rates between BIOL and CON patients (Table 5).
Adjusted for this factor, no difference (p = 0.99) between the
groups was found.
Some patients also switched from no remission to remission,
resulting in an increase in the DAS28 remission rates between
months 6 and 12 (BIOL, 13.5% to 16.3% (p = 0.07); CON,
12.5% to 15.3% (p = 0.47)); however, this increase was not
significant.
Functional outcome
The number of functionally independent patients (FFbH ≥67)
increased from 270 (34.2%) at start of treatment to 394
(49.9%) at 12 months (p < 0.001) in the BIOL group and from
122 (47.7%) to 155 (60.5%) (p < 0.001) in the control group.
In the subgroup of patients with severe disability at baseline
(FFbH ≤50 or HAQ >1.75) 78/363 (21.5%) of the BIOL com-
pared to only 8/85 (9.4%) of the CON patients (p = 0.01)
achieved at least functional independence. This difference
between BIOL and CON patients was even higher when other
risk factors of functional outcome were taken into account.
Adjusted for baseline functional capacity, comorbid conditions
and number of DMARD failures, an approximately four times
higher chance (BIOL versus CON, OR = 3.88; anti-TNF group
versus CON, OR = 4.08) of achieving functional independ-
ence was found (Table 6).
At the start of treatment, 61 (19.9%) of the controls but only
111 (11.6%) of the BIOL patients had a functional status of
>83% of full function ('functional remission'; p < 0.001).
These percentages increased to 30.1% in CON and 26.7% in
BIOL patients at 12 months. In patients with a functional sta-
tus below physical independence (<67) at baseline, functional
remission was achieved in 12 (8.3%) of the controls but in 73
(13.2%) of the BIOL patients. In patients with a FFbH <67,
however, BIOL patients differed significantly with respect to
important predictors of functional remission from controls at
baseline. They had a significantly worse (p = 0.01) functional
capacity, significantly more DMARD failures, a significantly
higher disease activity (DAS28, SJC, TJC, pain), and signifi-
cantly higher propensity scores. After adjustment for baseline
status using multivariate logistic regression, a significant differ-
ence between BIOL and CON was found (Table 6). In addition
to the functional status at baseline and the treatment, the pro-
pensity score, age, and pain remained significant predictors of
functional remission (Table 6). A better functional outcome
was in particular found in patients receiving etanercept, inflixi-
mab or adalimumab, whereas the outcome in anakinra patients
was similar to controls (Table 6).
The chance to maintain functional remission or physical inde-
pendence was higher than the chance to maintain clinical
remission. Most of the severely disabled patients (85.4%) who
achieved an FFbH ≥67 at 6 months maintained this functional
Table 5
Disease activity at 12 months for patients in DAS28 remission 
at 6 months.
Disease activity at 12 months BIOL, n (%) CON, n (%)
In remission (DAS28 <2.6) 56 (54.9%) 18 (58.1%)
Low disease activity (DAS28 <3.2) 17 (16.7%) 7 (22.6%)
Moderate or high disease activity 
(DAS28 >3.2)
29 (28.4%) 6 (19.4%)
Total 102 31
BIOL, patients treated with biologics; CON, patients receiving 
conventional DMARD treatment (control group); DAS28, disease 
activity score based on 28 joint counts.Available online http://arthritis-research.com/content/8/3/R66
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status at 12 months. Likewise, 77.2% of the patients who
were in functional remission at 6 months achieved this status
also at 12 months.
Discussion
The introduction of biologic agents has substantially increased
the options for treatment of RA and significantly improved the
outcome. To achieve a status of low disease activity or even
remission has become a realistic goal of treatment. Interest-
ingly, this is the case not only for patients treated with these
new agents but also for patients treated with conventional
DMARDs. This study was conducted to investigate the remis-
sion rates according to two different criteria and the achieve-
ment of two endpoints for functional outcome (functional
remission and functional independence) in a cohort of patients
treated with biologics in daily practice and to compare these
results with a control group of patients who changed their con-
ventional DMARD treatment because of inefficacy or intoler-
ance.
Of the BIOL patients, 16% achieved a DAS28 <2.6 at 12
months and 13% achieved remission according to the modi-
Table 6
Adjusted odds ratios of physical independence and normal functionat 12 months.
Achievement of FFbH ≥67 (physical 
independence)
Achievement of FFbH ≥83 (functional 
remission)
Univariate Multivariate Univariate Multivariate
OR 95% CI Adj. OR 95% CI OR 95% CI Adj. OR 95% CI
FFbHa 1.54 1.23–1.92 1.51 1.20–1.90 1.84 1.51–2.23 1.85 1.50–2.29
Propensity score (scale: 0 to 1)b 0.96 0.85–1.09 0.93 0.84–1.04 0.85 0.74–0.98
Rheumatoid factor positive 0.99 0.51–1.90 0.67 0.38–1.16
Number of previous DMARDs
4 to 5 versus 2 to 3 0.73 0.44–1.20 0.67 0.39–1.15 0.52 0.31–0.86
≥6 versus 2 to 3 0.40 0.17–0.94 0.39 0.16–0.94 0.50 0.23–1.10
Swollen joint count 1.03 0.99–1.07 1.01 0.97–1.05
Tender joint count 1.01 0.97–1.04 0.98 0.95–1.01
ESRa 0.96 0.86–1.06 0.95 0.86–1.05
DAS28 1.08 0.86–1.34 0.90 0.74–1.10
Pain (0 to 10) 1.05 0.92–1.19 1.02 0.91–1.15 1.22 1.05–1.40
Female 0.79 0.44–1.40 0.94 0.53–1.68
Agea 0.70 0.56–0.88 0.62 0.51–0.76 0.64 0.51–0.80
Disease duration (years) 0.95 0.92–0.98 0.94 0.91–0.97
Disease duration ≤2 years versus >2 years 1.21 0.39–3.78 1.59 0.64–3.96
Any comorbidity, yes versus no 0.38 0.23–0.62 0.42 0.25–0.71 0.46 0.28–0.73
Osteoporosis, yes versus no 0.47 0.27–0.83 0.43 0.24–0.78
BIOL versus CON 2.63 1.22–5.69 3.88 1.71–8.79 1.68 0.89–3.19 2.18 1.04–4.57
Anti-TNF agents versus CON 2.77 1.28–6.00 4.09 1.80–9.29 1.73 0.91–3.29 2.21 1.06–4.63
Anakinra versus CON 0.57 0.07–4.83 0.79 0.09–7.20 0.82 0.17–3.88 1.33 0.26–6.94
The achievement of FFbH ≥67 was investigated only in severely disabled patients with high risk of needing external help (FFbH ≤50, cutoff point 
used to identify severely disabled patients with a high risk of needing external help) [13] before the start of treatment (BIOL, n = 452 (anti-TNF 
agents, n = 425; anakinra, n = 27); CON, n = 100); the achievement of FFbH >83 was investigated only in patients who were at any risk of 
needing external help (FFbH <67, cut-off point used to identify patients who were under any increased risk of needing external help) [13], (BIOL, 
n = 682 (anti-TNF agents, n = 643; anakinra, n = 39); CON, n = 173). Results of different univariate and multivariate logistic regression analyses. 
Final multivariate models were found by stepwise regression. aThe ORs refer to 10 units of the parameter. bOR refer to 0.1 units of the propensity 
score. Adj. OR, adjusted odds ratio; BIOL, patients treated with biologics; CI, confidence interval; CON, patients receiving conventional DMARD 
treatment (control group); CRP, C-reactive protein; DAS28, disease activity score based on 28 joint counts; DMARD, disease modifying anti-
rheumatic drugs; ESR, erythrocyte sedimentation rate; FFbH, Funktionsfragebogen Hannover (Hannover Functional Status Questionnaire); TNF, 
tumor necrosis factor.Arthritis Research & Therapy    Vol 8 No 3    Listing et al.
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fied ARA criteria. The figures in the control group were 15%
and 10%, respectively. Adjusting for differences in the case
mix, we found that biologics doubled the chance of remission
in active RA patients treated in routine care.
Sustained remission over a longer period of time is difficult to
achieve [8,20,21]. Approximately half of our patients in remis-
sion at six months relapsed at 12 months, although they were
under continuing rheumatologic care. This proportion is high,
but it is in agreement with the findings of others [8,20,21]. For
this reason, the original ARA criterion is likely to be stronger
than the DAS28 criterion, since it requires ongoing remission
for at least two months and also a complete absence of symp-
toms in the feet, which are not included in the calculation of the
DAS28. These differences are more important [22] than the
calculation of other cutoff values for the DAS28 remission as
proposed by others [16,23,24].
To evaluate differences in remission rates, the risk profile of the
patients treated had to be taken into account. Disease activity
at start of treatment [21,25], disease severity, age, previous
DMARD failures and comorbidities [26] indicating disease
severity (for example, corticoid induced osteoporosis) were
found to influence the achievement of remission. The DAS28
at baseline was the strongest predictor of remission in our
data, more important than single joint counts or ESR. The
chance of remission decreased with an increasing DAS28.
We found that in addition to the DAS28, markers of disease
severity such as rheumatoid factor [21,25], disability [21] or
osteoporosis were significantly associated with the outcome.
Higher rates of remission were found in patients with up to two
years of disease duration. As the number of patients with early
RA was too small in our data, this difference did not reach sta-
tistical significance. However, the small number of patients
with early disease likely explains the differences between the
remission rates found in this study and the distinctly higher
rates found by others in recent onset RA [27,28]. Our remis-
sion rates at 12 months are comparable to those found in rou-
tine care (16% in [29] and 14% in [30]) or under treatment
with etanercept alone or MTX alone (18% and 17%, respec-
tively) [20]. Van der Heijde and colleagues [20] reported
higher DAS28 remission rates (38%) in patients receiving a
combination therapy of etanercept and MTX. Of note, patients
enrolled into the TEMPO trial (Trial of Etanercept and Meth-
otrexate with Radiographic Patient Outcomes) [20,31] had a
higher a priori chance of remission because of a lower number
of previous DMARD failures (2.3 on average; no failure of a
MTX therapy) and a lower percentage of positive rheumatoid
factor (76%) than our patients [31]. We found higher treat-
ment continuation rates in patients treated with anti-TNF
agents in combination with MTX compared to those receiving
anti-TNF drugs alone [10], but we did not find any significant
differences in the remission rates between both subgroups.
More detailed analyses may be needed to determine the rea-
sons for this finding; these analyses were beyond the scope of
this paper.
Grigor and colleagues [29] showed that intensive care with a
tight control of disease activity can lead to very high DAS
remission rates (65%). The fact that in comparison to our
patients, their patients had better preconditions regarding pre-
dictors of remission, such as disease duration or previous
DMARD combination therapy, still does not provide a feasible
explanation for the large difference in the remission rates.
Therefore, further evaluation of this treatment strategy is
needed.
It has been shown in randomized controlled trials that biolog-
ics can effectively improve function [2-5,32,33]; however,
most of these trials excluded severely disabled patients
[1,2,5,31,32]. This is in contrast to daily rheumatologic care in
which severely disabled patients are preferred candidates for
biologic treatment. Our findings suggest that especially
severely disabled patients benefit from treatment with biolog-
ics. In these patients, the chance to achieve physical inde-
pendence was found to be approximately four times higher if
treated with biologics compared to conventional DMARDs.
Furthermore, sub-sample patients who were below the thresh-
old of physical independence at baseline were significantly
more likely to achieve functional remission when a treatment
with biologics was chosen.
Conclusion
Our results complement the knowledge from clinical trials. We
found that biologics, in particular anti-TNF agents, increase the
chance to achieve clinical remission and a status of functional
remission or at least physical independence in RA patients
treated in routine care. Furthermore, in severely disabled
patients with long-standing disease, significant improvement
with the ability to live an independent life can be achieved by
a treatment with etanercept, infliximab or adalimumab. How-
ever, temporary or even sustained remission remain ambitious
aims, which are achieved in a minority of patients only.
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